Further testing of brain-penetrant HDAC6 inhibitors, particularly those with improved metabolic stability, could provide additional validation of this therapeutic approach for AD, PD, and related neurodegenerative diseases. The gene discussed is HDAC6; the disease is neurodegenerative disease.